Qi He

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Correction: The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.

Correction: The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.

Journal: Oncogene

Published: April 15, 2026

Prognostic Significance of Different Ki-67 Cutoff Values Defined Luminal B HER2-Negative Breast Cancer.

Prognostic Significance of Different Ki-67 Cutoff Values Defined Luminal B HER2-Negative Breast Cancer.

Journal: Cancer investigation

Published: February 02, 2026

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2025

Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping.

Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping.

Journal: Women & health

Published: December 28, 2022

Clinicopathological features and prognoses of very young patients (≤35 years) with breast cancer: a retrospective population-based study in China.

Clinicopathological features and prognoses of very young patients (≤35 years) with breast cancer: a retrospective population-based study in China.

Journal: Chinese medical journal

Published: July 21, 2022

Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.

Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.

Journal: Translational cancer research

Published: May 12, 2022

The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.

The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.

Journal: Oncogene

Published: December 27, 2021

AC016405.3 functions as an oncogenic long non-coding RNA by regulating ERBB3 via sponging miR-22-3p in breast cancer.

AC016405.3 functions as an oncogenic long non-coding RNA by regulating ERBB3 via sponging miR-22-3p in breast cancer.

Journal: Journal of clinical laboratory analysis

Published: May 19, 2021

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 11, 2020

Screening of Prognostic Factors in Early-Onset Breast Cancer.

Screening of Prognostic Factors in Early-Onset Breast Cancer.

Journal: Technology in cancer research & treatment

Published: February 08, 2020

Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer.

Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer.

Journal: Oncology letters

Published: June 27, 2019

Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.

Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.

Journal: Disease markers

Published: March 01, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026